A
PACB icon

Astrantus’s Pacific Biosciences PACB Stock Holding History

Astrantus’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$116K Buy
+12,700
New +$146K 0.2% 172

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Astrantus's PACB Position: Q1 2022 in Review

Astrantus opened a new position in Pacific Biosciences (PACB) in Q1 2022: 12,700 shares worth $116K. The stake represents 0.2% of the portfolio and ranks #172 among its holdings.

249 funds tracked by Wall St. Rank hold PACB as of Q1 2022.

  • Astrantus held 12,700 shares of Pacific Biosciences worth $116K as of Q1 2022.
  • Pacific Biosciences was a new Astrantus position in Q1 2022.
  • Pacific Biosciences made up 0.2% of Astrantus's portfolio in Q1 2022, its #172 holding.
  • 249 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.